Bayer's Dual Track: Orphan Status for BlueRock Therapy, Fresh Roundup Trial in Missouri
Published on 09/30/2026 at 15:10 | Editorial boerse-global.de
Bayer finds itself pulled in two directions this Wednesday, with its pharmaceutical unit celebrating a regulatory milestone while its legal team braces for another courtroom battle over the company's Monsanto legacy.
On the research front, the Leverkusen-based DAX group and its subsidiary BlueRock Therapeutics secured orphan drug designations from both the US Food and Drug Administration and the European Medicines Agency for their experimental iPSC cell therapy Lemiretprocel, also tracked internally as OpCT-001. The FDA's designation covers retinitis pigmentosa and cone-rod dystrophy, while the EMA's framework spans inherited retinal diseases — IRDs — with rod- or cone-dominant phenotypes. Such status is designed to smooth the path for therapies targeting rare conditions by offering regulatory and financial incentives.
The candidate is still in its early days. Lemiretprocel, built on induced pluripotent stem cells, is being tested in the Phase 1/2a CLARICO trial, which evaluates safety and efficacy in patients with primary photoreceptor diseases. No regulatory approval exists for the therapy in any market, and its safety and effectiveness have yet to be fully established. Even so, the twin designations represent a meaningful step for the German conglomerate as it builds out a cell therapy platform.
Pipeline Momentum Beyond Cell Therapy
Progress is not confined to BlueRock. Bayer recently launched MiraSOFT in the self-medication segment, adding a treatment option containing docusate sodium for occasional constipation to its gastrointestinal portfolio. Elsewhere in the pipeline, the FDA granted priority review to elinzanetant — a compound inherited from the acquisition of biotech firm KaNDy Therapeutics — for relieving symptoms in breast cancer patients undergoing endocrine therapy. The drug is already approved in the US and Europe under the brand name Lynkuet for vasomotor symptoms associated with menopause.
Should investors sell immediately? Or is it worth buying Bayer?
A New Legal Playbook in Missouri
While the science side advances, the courtroom story continues to weigh on sentiment. A fresh trial against Monsanto opened Wednesday in the US state of Missouri, where three cancer patients allege the company failed to adequately test its glyphosate-based herbicide Roundup for risks before selling it. One of the plaintiffs died before proceedings began.
What sets this case apart is the legal strategy. The plaintiffs are arguing that the product was defectively designed and insufficiently safe — an approach that sidesteps earlier US Supreme Court rulings which had made failure-to-warn cancer claims harder to pursue. Bayer rejects the allegations, pointing to existing regulatory safety reviews including those by the US Environmental Protection Agency. The current plaintiffs are not part of the multibillion-dollar settlement the company is seeking.
Legal Overhang Meets Market Caution
Roundup litigation has dogged Bayer since its 2018 acquisition of Monsanto. Roughly 65,000 cases remain open in the US, and each new court date draws close attention from investors looking for signals about the viability of planned settlements.
The stock traded at EUR 48.91 on Wednesday, slipping 0.3%, though it has climbed 32% since the start of the year. A separate reading earlier in the session had the shares up 0.4% at EUR 49.25, with the equity bumping against technical resistance. Market watchers point to persistent uncertainty over the glyphosate litigation as a recurring brake on breakout attempts. Until the legal legacy is fully resolved, trial headlines look set to remain a defining force in how the company is valued.
Ad
Bayer Stock: New Analysis - 30 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
